Gemcitabine Intravesical Solution Recalled for Lack of Sterility Assurance
Edge Pharma is recalling approximately 627 syringes of Gemcitabine Sterile Intravesical Solution nationwide because the manufacturer cannot guarantee the product is sterile. The recalled batches were distributed between December 2021 and February 2022.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable drug where the primary hazard is potential microbial contamination from lack of sterility assurance. Although no illnesses or injuries are reported in the source text, the product is used intravesically (directly into the bladder) and lack of sterility poses a direct risk of serious infection in high-risk patient populations. This hazard profile and product route of administration justify a High severity rating.
Plain-English summary
Edge Pharma, LLC is recalling Gemcitabine, Sterile Intravesical Solution, Preservative Free (1g/50mL, 20 mg/mL) in single-dose 50 mL syringes due to lack of assurance of sterility. The recalled product includes 627 syringes distributed nationwide, with lot codes dating from December 2021 to February 2022.
The recall affects the product NDC 05446-1566-50 manufactured at Edge Pharma's facility in Colchester, Vermont. Because the sterility of these syringes cannot be assured, patients who receive the product may be at risk of infection.
Consumers and healthcare providers who have received affected batches should discontinue use immediately. Anyone with questions about whether they have received a recalled batch should contact Edge Pharma directly or consult their healthcare provider.
The recalled product
- Product
- Gemcitabine, Sterile Intravesical Solution, Preservative Free, 1g/50mL (20 mg/mL), 50 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1566-50
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Injectable Solution
- Affected units
- 627
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- 08-2021-18@1 12/14/2021
- 08-2021-27@1 12/09/2021
- 09-2021-01@4 12/14/2021
- 09-2021-08@2 12/21/2021
- 09-2021-14@6 01/05/2021
- 09-2021-16@4 12/29/2021
- 09-2021-17@4 12/30/2021
- 09-2021-22@3 01/04/2022 & 10-2021-27@3 02/08/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 56 recalled by Edge Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Edge Pharma, LLC
See all →- ModerateProfound-PE Dental Gel Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
- SevereMVASI Sterile Ophthalmic Solution Lacks Assured Sterility
FDA (Drugs) · 2022-02-02
- ModerateLET Topical Gel drug recall for CGMP deviations
FDA (Drugs) · 2022-02-02
- SevereVancomycin HCl Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2022-02-02
- ModerateCSF-HC Otic Powder Drug Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22